Please login to the form below

Not currently logged in
Email:
Password:

Novel HIV treatment shows promise

Myriad Pharmaceuticals' HIV treatment MPC-4326 "safe and well tolerated"

Myriad Pharmaceuticals' HIV treatment MPC-4326 is safe and well tolerated according to two abstracts presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting on 12–15 September in San Francisco, US.

MPC-4326 is the first 'maturation inhibitor' a new class of HIV drug that inhibits the final step in the processing of the HIV Gag protein. Treatments with novel mechanism of action are though to be critical to combat drug resistance to available HIV therapies.

"I am very excited that the new 100 mg tablet formulation of MPC-4326 has performed so well," said Dr Adrian Hobden, President and CEO of the Salt Lake City-based biopharmaceutical company. "Coupled with the potential companion diagnostic and the significant viral load reductions seen in these two studies, we believe that we have a clear clinical path forward."

15th September 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics